Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics

Hughes, 2002, Guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 34, 730, 10.1086/339215 Segal, 2008, Prevention and treatment of cancer-related infections, J Natl Compr Canc Netw, 6, 122 Link, 2003, Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Ann Hematol, 82, S17 Voog, 2000, Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system, J Clin Oncol, 18, 325, 10.1200/JCO.2000.18.2.325 Intragumtornchai, 2000, A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma, Leuk Lymphoma, 37, 351, 10.3109/10428190009089435 Kloess, 1999, Predicting hematotoxicity in multicycle chemotherapy, Blood, 94, 87a Aslani, 2000, The predictive value of body protein for chemotherapy-induced toxicity, Cancer, 88, 796, 10.1002/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO;2-P Blay, 1996, Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia, J Clin Oncol, 14, 636, 10.1200/JCO.1996.14.2.636 Lyman, 2005, Risk models for predicting chemotherapy-induced neutropenia, Oncologist, 10, 427, 10.1634/theoncologist.10-6-427 Lyman, 2002, Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis, Am J Med, 112, 406, 10.1016/S0002-9343(02)01036-7 Kuderer, 2007, Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review, J Clin Oncol, 25, 3158, 10.1200/JCO.2006.08.8823 Pinto, 2007, Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials, Curr Med Res Opin, 23, 2283, 10.1185/030079907X219599 Gridelli, 2007, Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel, Crit Rev Oncol Hematol, 63, 53, 10.1016/j.critrevonc.2007.01.008 Gafter-Gvili, 2005, Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients, Ann Intern Med, 142, 979, 10.7326/0003-4819-142-12_Part_1-200506210-00008 Cullen, 2005, Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas, N Engl J Med, 353, 988, 10.1056/NEJMoa050078 Bucaneve, 2005, Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia, N Engl J Med, 353, 977, 10.1056/NEJMoa044097 Leibovici, 2006, Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions, Cancer, 107, 1743, 10.1002/cncr.22205 Cometta, 1994, Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia, N Engl J Med, 330, 1240, 10.1056/NEJM199404283301717 Gafter-Gvili, 2007, Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis, J Antimicrob Chemother, 59, 5, 10.1093/jac/dkl425 Prentice, 2001, Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients A strategy for the prevention of emergence of antimicrobial resistance, Br J Haematol, 115, 46, 10.1046/j.1365-2141.2001.03034.x Cullen, 2007, Rational selection of patients for antibacterial prophylaxis after chemotherapy, J Clin Oncol, 25, 4821, 10.1200/JCO.2006.08.7395 Gilbert, 1994, Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support, J Clin Oncol, 12, 1005, 10.1200/JCO.1994.12.5.1005 de Marie, 1993, Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination, Eur J Clin Microbiol Infect Dis, 12, 897, 10.1007/BF01992162 Bow, 1995, Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones, Clin Infect Dis, 20, 907, 10.1093/clinids/20.4.907 Elting, 2008, Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia, J Clin Oncol, 26, 606, 10.1200/JCO.2007.13.8222 Bow, 1988, Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukaemia. The trade-off for reduced gram-negative sepsis, Am J Med, 84, 847, 10.1016/0002-9343(88)90062-9 Kuderer, 2006, Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, Cancer, 106, 2258, 10.1002/cncr.21847 Timmer-Bonte, 2005, Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study, J Clin Oncol, 23, 7974, 10.1200/JCO.2004.00.7955 Timmer-Bonte, 2006, Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer, J Clin Oncol, 24, 2991, 10.1200/JCO.2005.04.3281 von Minckwitz, 2008, Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer Results from the GEPARTRIO study, Ann Oncol, 19, 292, 10.1093/annonc/mdm438 Fortner, 2006, A prospective investigation of chemotherapy-induced neutropenia and quality of life, J Support Oncol, 4, 472 Infectious Diseases Society of Taiwan; Hematology Society of Taiwan; Medical Foundation in Memory Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccine. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005;38(Decmeber(6)):455–7. Masaoka, 2004, Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary, Clin Infect Dis, 39, S49, 10.1086/383054 Imran, 2008, Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials, Eur J Clin Microbiol Infect Dis, 1, 53 Aapro, 2006, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, Eur J Cancer, 42, 2433, 10.1016/j.ejca.2006.05.002 Crawford, 2007, Myeloid growth factors, Clinical practice guidelines in oncology, J Natl Compr Canc Netw, 5, 188, 10.6004/jnccn.2007.0019 Smith, 2006, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, 24, 3187, 10.1200/JCO.2006.06.4451 Engels, 1998, Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis, J Clin Oncol, 3, 1179, 10.1200/JCO.1998.16.3.1179 Crawford, 2008, Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice, J Natl Compr Canc Netw, 2, 109, 10.6004/jnccn.2008.0012 Budman, 1998, Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer The Cancer and Leukemia Group B, J Natl Cancer Inst, 90, 1205, 10.1093/jnci/90.16.1205 Kwak, 1990, Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis, J Clin Oncol, 8, 963, 10.1200/JCO.1990.8.6.963 Bonadonna, 1995, Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up, N Engl J Med, 6332, 901, 10.1056/NEJM199504063321401 Lepage, 1993, Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol The GELA. (Groupe d’Etude des Lymphomes de l’Adulte), Ann Oncol, 8, 651, 10.1093/oxfordjournals.annonc.a058619 Chang, 2000, Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer, Eur J Cancer, 36, S11, 10.1016/S0959-8049(99)00259-2 Mayers, 2001, Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma, Cancer, 91, 2246, 10.1002/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4 Wood, 1994, Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma, N Engl J Med, 330, 1253, 10.1056/NEJM199405053301801 Bohlius J, Reiser M, Schwarzer G, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma [Update of Cochrane Database Syst Rev. 2002]. Cochrane Database of Systematic Reviews CD003189; 2004. Lyman, 2003, Epidemilogy of febrile neutropenia, Supportive Cancer Therapy, 1, 23, 10.3816/SCT.2003.n.002 Lyman, 2002, Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients, Curr Opin Hematol, 9, 207, 10.1097/00062752-200205000-00006 Frankfurt, 2007, Growth factors in leukemia, J Natl Compr Canc Netw, 2, 203, 10.6004/jnccn.2007.0020 Timmer-Bonte, 2006, Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer, J Clin Oncol, 24, 2991, 10.1200/JCO.2005.04.3281 Vogel, 2005, First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study, J Clin Oncol, 23, 1178, 10.1200/JCO.2005.09.102 Elting, 1992, Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors, Clin Infect Dis, 6, 1201, 10.1093/clinids/14.6.1201 Pagliuca, 2003, Haemato-Oncology Task Force of the British Committee for Standards in Haematology Guidelines on the use of colony-stimulating factors in haematological malignancies, Br J Haematol, 1, 22, 10.1046/j.1365-2141.2003.04546.x Crawford, 1991, Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer, N Engl J Med, 325, 164, 10.1056/NEJM199107183250305 Timmer-Bonte, 2008, Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy, J Clin Oncol, 26, 290, 10.1200/JCO.2007.13.0898 Lyman, 1998, The economics of febrile neutropenia: implications for the use of colony-stimulating factors, Eur J Cancer, 12, 1857, 10.1016/S0959-8049(98)00222-6 Lyman, 2006, Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy, J Clin Oncol, 24, 483, 10.1200/jco.2006.24.18_suppl.8561 Silber, 1998, First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy, J Clin Oncol, 7, 2392, 10.1200/JCO.1998.16.7.2392 Cruciani, 2003, Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients, J Clin Oncol, 1521, 4127, 10.1200/JCO.2003.01.234 Tjan-Heijnen, 2001, Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study, Ann Oncol, 12, 1359, 10.1023/A:1012545507920 Lyman, 2003, OPPS Working Group; ANC Study Group Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy, Leuk Lymphoma, 44, 2069, 10.1080/1042819031000119262 Tascini, 1999, Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center, Clin Microbiol Infect, 5, 457, 10.1111/j.1469-0691.1999.tb00175.x Reuter, 2005, Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies, Clin Infect Dis, 40, 1087, 10.1086/428732 Arup, 2007, Granulocyte Colony-Stimulating Factor/Granulocyte Colony-Stimulating Factor Receptor Biological Axis Promotes Survival and Growth of Bladder Cancer Cells, Urology, 69, 1210, 10.1016/j.urology.2007.02.035 Morales-Arias, 2007, Expression of Granulocyte-Colony-Stimulating Factor and Its Receptor in Human Ewing Sarcoma Cells and Patient Tumor Specimens: Potential Consequences of Granulocyte-Colony-Stimulating Factor Administration, Cancer, 110, 1568, 10.1002/cncr.22964 Mroczko, 2004, Hematopoietic cytokines as tumor markers, Clin Chem Lab Med, 42, 1347, 10.1515/CCLM.2004.253 Gutschalk, 2006, Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo, Cancer Res, 66, 8026, 10.1158/0008-5472.CAN-06-0158 Uemura, 2007, Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: Roles of cyclooxygenase-2, Oncol Rep, 17, 955 Hershman, 2007, Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy, J Natl Cancer Inst, 99, 196, 10.1093/jnci/djk028 Morrison, 2007, Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices, J Manag Care Pharm, 13, 337, 10.18553/jmcp.2007.13.4.337 Weycker, 2008, Risk of hospitalization with Pegfilgrastim versus filgrastim prophylaxis: A retrospective cohort study, J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.6580 Eldar-Lissai, 2008, Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy, Value in Health, 11, 171, 10.1111/j.1524-4733.2007.00242.x Citron, 2003, J Clin Oncol, 21, 1431, 10.1200/JCO.2003.09.081 Pfreundschuh, 2004, 2-weekly vs. 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the NHL-B-2 trial of the DSHNHL, Blood, 104, 634, 10.1182/blood-2003-06-2095 Pfreundschuh, 2004, 2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with good prognosis (low LDH) aggressive non-Hodgkin's lymphoma: results of the NHL-B-1 trial of the DSHNHL, Blood, 104, 626, 10.1182/blood-2003-06-2094 Verdonck, 2007, Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Blood, 109, 2759, 10.1182/blood-2006-07-035709 Sternberg, 2001, J Clin Oncol, 19, 2638, 10.1200/JCO.2001.19.10.2638 Sternberg, 2006, Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours, Euro J Cancer, 42, 50, 10.1016/j.ejca.2005.08.032 Kalil, 2008, Meta-analysis under the spotlight: we must differentiate its limitations versus its prejudices, Crit Care Med, 36, 3124, 10.1097/CCM.0b013e31818bdea3